Zydus Lifesciences and Amplitude Surgical SA confirm that Amplitude has conducted the mandatory information and consultation process with the works council of Amplitude SAS. Consequently, Zydus has ...

Following the joint announcement of March 11, 2025, Zydus Lifesciences Limited ("Zydus") and Amplitude Surgical SA ...

Private equity activity in healthcare remained resilient with 42 deals worth $562 million, just shy of last quarter’s $603 ...

Sight Sciences, Inc. has announced the launch of the OMNI® Edge Surgical System, an advanced technology designed for minimally invasive glaucoma surgery (MIGS). The new system will be showcased ...

(MENAFN- GlobeNewsWire - Nasdaq) New system features higher viscoelastic capacity and TruSyncTM technology, engineered to safely synchronize surgical control and precision in implant-free ...

Zydus MedTech Private Limited, a wholly owned subsidiary of Zydus Lifesciences Limited specializing in medical ... particularly for elderly patients or those at high surgical risk. By replacing the ...

Ahmedabad: Keeping its cardiac focus in the medical device sector, Zydus MedTech, a wholly owned subsidiary of Indian pharma major Zydus Lifesciences ... device maker Amplitude Surgical for ...

As it aims to broaden the reach of its replacement heart valves among younger patients, Edwards Lifesciences has put ... that compared the performance of surgical aortic valves made with its ...

The ruling blocks Lupin and Zydus Life from selling their generic version of Mirabegron, the bioequivalent of Astellas' overactive bladder drug, Myrbetriq, in the United States. According to the ...

"We stand united with Braile to improve patient outcomes and expand access to advanced, critical cardiovascular care globally," Zydus Lifesciences MD Sharvil Patel said in a statement. This technology ...

Considering the 85.6% of the capital that will be acquired by Zydus Lifesciences Limited from PAI Partners, the management of Amplitude Surgical and two minority shareholders, Zydus Lifesciences ...

Pennington: Zydus Lifesciences' venture capital arm ... This approach aims to provide BCC patients with a non-surgical treatment option that improves outcomes. Additionally, Feldan is advancing a ...